TICKERNERD
Menu
ADGMADGMHealthcare · Medical Devices

ADGM Stock Forecast: Adagio Medical Holdings, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$0.13
−2.99% on the day

The 3 Wall Street analysts covering Adagio Medical Holdings, Inc. hold a median 12-month price target of $3 — +2207.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 34 of 100 as at 8 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$3.6M
Ticker Nerd rank
34 / 100
Median analyst target
$3.00
Analysts covering
3
Revenue$0.0
Operating income−$4.9M
Net income−$6.7M
Free cash flow−$5.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−16.7%
1M
−78.6%
YTD
−87.5%
1Y
−94.2%
From 52W high
−94.5%
From 52W low
0.0%
$0.13
$2.35
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ADGM stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Adagio Medical Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
34 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
98
Growth
94
Accruals
83
Revisions
52
Momentum
33
Volatility
12
Quality
8
Issuance
6
Value
3

Size (98): Smaller than most of the companies we track.

Value (3): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ADGM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ADGM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$1.00$2.00$3.00$4.00Jan 26Apr 26Jul 26Oct 26ADGMHigh $4.00Median $3.00Low $3.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
3 Buy0 Hold0 Sell
Low $3.00Median $3.00High $4.00

The green dot is the last close — the median target sits +2207.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
3 June 2026LUCID CAPITAL MARKETSInitiatesBuy$3.00
14 Apr 2026Piper SandlerInitiatesOverweight—
2 Dec 2025Lake StreetInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ADGM appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ADGM vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Adagio Medical Holdings, Inc. returned −94.2% against +16.2% for the S&P 500, dividends included.

ADGM vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Jan 26Apr 26Jul 26Oct 26ADGMS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ADGM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
2
Fundamentals

Adagio Medical Holdings, Inc. (ADGM) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.1×

Cheaper than 77% of US stocks

Price / sales
—
Price / book
−7.2×

Cheaper than 97% of US stocks

EV / EBITDA
−1.1×

Cheaper than 69% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−657.8%

Higher than 2% of US stocks

Return on assets
−35.5%

Higher than 12% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Adagio Medical Holdings, Inc. (ADGM) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Adagio Medical Holdings, Inc. has a market value of $3.6M and an enterprise value of $21.2M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$27.1M.

  • Diluted earnings per share, trailing twelve months: $−1.48.

  • Free cash flow in the twelve months to 30 June 2026: −$16.6M.

  • Shares outstanding: 22.2M.

  • Trailing P/E: −0.1×; forward P/E: −0.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Adagio Medical Holdings, Inc. employs 41 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Oct 2026

Data provided by Twelve Data

Peers

ADGM vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
ADGMAdagio Medical Holdings, Inc.$3.6M
34
NUWENuwellis, Inc.$2.5M
15
NXLNexalin Technology, Inc.$3.4M
33
XAIRBeyond Air, Inc.$2.2M
36
IVFINVO Fertility, Inc.$3.5M
31
VJETFlyte Aviation, Inc.$2.1M
26
BJDXBluejay Diagnostics, Inc.$3.6M
17

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Adagio Medical Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ADGM news & analysis

Adagio Medical Announces Strategic Review Process to Maximize Shareholder Value

Business Wire · 23 Sept 2026neutral

Adagio Medical Holdings announced that its Board of Directors completed a comprehensive review of the Company's business, programs, resources and capabilities, and has initiated a formal process to explore strategic alternatives focused on maximizing shareholder value.

Why it matters — A formal strategic review signals that the Company's direction and future ownership could change, which ADGM watchers would monitor closely for shareholder-value implications.

Adagio Medical Highlights First Patient Treated in IDE Study Evaluating Next-Generation vCLAS™ Ultra System for Ventricular Tachycardia at Banner – University Medical Center Phoenix

Business Wire · 16 Sept 2026positive

Adagio Medical announced that the first patient in its IDE study evaluating the next-generation vCLAS Ultra Ultra-Low Temperature Ablation Ventricular Ablation System was treated at Banner – University Medical Center Phoenix. The study is designed to support a Premarket Approval supplement to the company's existing PMA.

Why it matters — The first patient treated in this pivotal study marks progress toward potential regulatory approval of a next-generation product in the company's ventricular tachycardia ablation pipeline.

Adagio Medical Reports Second Quarter 2026 Results

Business Wire · 11 Aug 2026positive

Adagio Medical Holdings, Inc. announced its financial results for the second quarter ended June 30, 2026. As a recent business highlight, the company treated the first patient with its next-generation vCLAS™ Ultra Ultra-Low temperature ablation catheter at the Hospital of the University of Pennsylvania.

Why it matters — ADGM watchers would care because the first-patient milestone for the next-generation vCLAS Ultra catheter signals progress in advancing the company's catheter ablation technology for cardiac arrhythmias.

Adagio Medical Treats First Patient with Faster, Single-Freeze Next-Generation ULTA System

Business Wire · 3 Aug 2026positive

Adagio Medical announced the successful treatment of the first patient using its next-generation vCLAS Ultra Ultra-Low Temperature Ablation (ULTA) system, under Expanded Access authorization from the U.S. Food and Drug Administration. The patient presented with non-ischemic cardiomyopathy, a type of cardiac arrhythmia condition the system is designed to treat.

Why it matters — This marks the first clinical use of Adagio's faster, single-freeze next-generation system, representing a key development milestone for the company's catheter ablation platform.

FAQ

Frequently asked questions about ADGM stock

What is the ADGM stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Adagio Medical Holdings, Inc. have a median 12-month price target of $3, with estimates ranging from $3 to $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ADGM stock a buy right now?

Of the 3 analysts covering Adagio Medical Holdings, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Adagio Medical Holdings, Inc. 34 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ADGM?

As at 8 Oct 2026, Adagio Medical Holdings, Inc. ranks 34 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (98 of 100).

Will ADGM stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +2207.7% from the last close, and Ticker Nerd's factor model ranks Adagio Medical Holdings, Inc. 34 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ADGM stock forecast for 2030?

No analyst covering Adagio Medical Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ADGM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $4 over the next 12 months.

How has ADGM stock performed over the past year?

Adagio Medical Holdings, Inc. returned -94.2% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Adagio Medical Holdings, Inc. do?

Adagio Medical Holdings, Inc. is a medical technology company focused on developing and commercializing catheter-based ablation systems for the treatment of cardiac arrhythmias.

What is the latest news on ADGM?

The most recent item we track (Business Wire, 23 Sept 2026): "Adagio Medical Announces Strategic Review Process to Maximize Shareholder Value". Adagio Medical Holdings announced that its Board of Directors completed a comprehensive review of the Company's business, programs, resources and capabilities, and has initiated a formal process to explore strategic alternatives focused on maximizing shareholder value.

Company

About Adagio Medical Holdings, Inc.

Adagio Medical Holdings, Inc. is a medical technology company focused on developing and commercializing catheter-based ablation systems for the treatment of cardiac arrhythmias. Its current portfolio includes the iCLAS atrial ultra-low temperature ablation system, the vCLAS ventricular ultra-low temperature catheter platform, and Cryopulse pulsed field cryoablation catheters. These technologies are designed to support physicians treating rhythm disorders such as atrial fibrillation and ventricular tachycardia, with an emphasis on delivering targeted lesion creation in cardiac tissue. Adagio Medical Holdings, Inc. operates as a healthcare device company serving the electrophysiology market, where catheter ablation plays an important role in minimally invasive heart rhythm management. Headquartered in Laguna Hills, California, the company concentrates on clinical and commercial use cases across cardiac arrhythmia care.

CEO Mr. Todd Usen · 41 employees · United States · https://adagiomedical.com